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Prognostic Value of Vascular Endothelial Growth Factor
Expression in Patients with Lung Cancer
A Systematic Review with Meta-Analysis
Ping Zhan, MD,* Jing Wang, MD,† Xiao-jing Lv, MD,* Qin Wang, MD,‡ Li-xin Qiu, MD,§
Xin-qing Lin, MD,* Li-ke Yu, MD,§ and Yong Song, MD, PhD*
Background: Vascular endothelial growth factor (VEGF) has been
implicated in tumorigenesis and metastasis, and it presumably me-
diates the proliferation of endothelial cells and promotes vascular
permeability. However, the prognostic value of VEGF overexpres-
sion in patients with lung cancer remains controversial.
Methods: Survival data from published studies were aggregated
following a methodological assessment. A systematic review of
eligible studies with meta-analysis was performed to quantitatively
review the correlation of VEGF overexpression with survival in
patients with lung cancer.
Results: We conducted a final analysis of 5386 patients from 51
studies. The studies were categorized by histology, disease stage,
patient race, VEGF isoform, and laboratory techniques used. Com-
bined hazard ratios suggested that VEGF overexpression had an
unfavorable impact on survival of patients with non-small cell lung
cancer (NSCLC) and small cell lung cancer (SCLC). However,
VEGFC and vascular endothelial growth factor receptor 3
(VEGFR3)/flt-1 overexpression did not significantly correlate with
survival in patients with NSCLC. In stage I–III NSCLC with VEGF,
the hazard ratio (95% confidence interval) was 1.46 (1.38–1.54)
overall, 1.35 (1.24–1.46) in Asian patients, 1.61 (1.49–1.73) in
non-Asian patients, 1.41 (1.17–1.65) in SCLC, 1.27 (1.06–1.47) in
adenocarcinoma, 1.57 (1.43–1.70) in stage I NSCLC, 1.46 (1.38–
1.55) in NSCLC by immunohistochemistry, 1.52 (1.23–1.81) in
NSCLC by reverse transcription-polymerase chain reaction, 1.22
(0.96–1.47) in NSCLC with VEGFC, and 1.58 (0.96–2.20) in
NSCLC with VEGFR3/flt-1. The data collected were not sufficient
to determine the prognostic value of VEGF in patients with squa-
mous cell lung carcinomas.
Conclusion: VEGF overexpression indicates a poor prognosis for
patients with NSCLC and SCLC; VEGFC and VEGFR3/flt-1 over-
expression was not significantly correlated with survival for patients
with NSCLC.
Key Words: Vascular endothelial growth factor, Prognosis, Lung
cancer, Meta-analysis.
(J Thorac Oncol. 2009;4: 1094–1103)
Lung cancer remains the deadliest cancer worldwide despiteimprovements in diagnostic and therapeutic techniques.1
Its incidence has yet to peak in many parts of world, partic-
ularly in China. The prognosis for lung cancer patients is
generally poor, with an overall 5-year survival rate of ap-
proximately 15%, and it has shown little improvement in
recent decades.2,3 Several independent prognostic factors for
survival have been identified: performance status, disease
stage, age, sex, and amount of weight lost.4 Some of these
factors are useful when choosing treatment options for an
individual, principally disease stage and performance status.
However, the discriminant value of most potential prognostic
biologic markers is insufficient to predict the optimal thera-
peutic course for an individual. For non-small cell lung
cancers (NSCLC) in earlier disease stages, surgery is a
potentially curative measure; for more advanced stages, che-
motherapy and radiotherapy are standard treatments. Never-
theless, the benefit of combination chemotherapy is limited,
and no significant benefit is associated with inadequate che-
motherapy. Thus, it is important to identify biologic markers
with predictive value for the survival of patients undergoing
treatment.
Angiogenesis, the formation of new tumor-feeding
blood vessels from preexisting vasculature, is critical for the
development and subsequent growth of human tumors and is
a prerequisite for metastasis. Proangiogenic factors secreted
by tumor cells and/or host factors stimulate endothelial cells
to proliferate and to form new blood vessels that are quali-
tatively poor and often leaky. As few as 60 to 200 tumor cells
can initiate angiogenesis. Although basic fibroblast growth
factor and platelet-derived growth factor are involved in
angiogenesis, proteins in the vascular endothelial growth
factor (VEGF) family are the predominant proangiogenic
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factors. The VEGF family of growth factors is comprised of
several structurally related molecules, including VEGFA,
VEGFB, VEGFC, and VEGFD.5,6 The major mediators of
tumor angiogenesis are VEGFA, usually referred to as
VEGF, and vascular endothelial growth factor receptor 2
(VEGFR2 or KDR/Flk-1). The binding of VEGF to VEGFR2
activates multiple signaling pathways,7 resulting in the up-
regulation of genes that promote the proliferation and migra-
tion of endothelial cells as well as their survival and vascular
permeability. Interestingly, the binding of VEGFC to VEGFR3
mediates lymphangiogenesis.
In addition, specifically targeted molecular therapy has
been anticipated as an effective addition to combination
chemotherapy. Recently, bevacizumab (a humanized mono-
clonal antibody directed against VEGF) was shown to in-
crease overall survival of patients with advanced NSCLC in
combination with standard chemotherapy in a randomized
phase 3 trial.8
The association between VEGF overexpression and
survival in patients with lung cancer has been studied for over
a decade. However, no consensus has been reached; conflict-
ing results have been reported from different laboratories. We
therefore carried out a meta-analysis of data from published
studies to quantitatively review the effect of VEGF overex-
pression in tumor tissue and/or blood serum on survival in
patients with lung cancer.
MATERIALS AND METHODS
Search Strategy and Study Selection
The electronic databases PubMed, Embase, Web of
Science, and CNKI (China National Knowledge Infrastruc-
ture) were searched for studies to include in the present
meta-analysis. An upper date limit of March 31, 2008 was
applied; we used no lower date limit. Searches included the
terms “lung cancer,” “VEGF,” “vascular endothelial growth
factor,” and “prognosis.” We also reviewed the Cochrane
Library for relevant articles. The references reported in the
identified studies were also used to complete the search.
Studies eligible for inclusion in this meta-analysis met
the following criteria: (1) measure VEGF expression in the
primary lung cancer tissue with immunohistochemistry (IHC)
or enzyme linked immunosorbent assay (ELISA)/reverse
transcription-polymerase chain reaction (RT-PCR); (2) pro-
vide information on survival (studies investigating response
rates only were excluded); (3) have a follow-up time exceed-
ing 5 years (3 years for SCLC); and (4)when the same author
reported results obtained from the same patient population in
more than one publication, only the most recent report, or the
most complete one, was included in the analysis. Two re-
viewers (P.Z. and J.W.) independently determined study
eligibility. Disagreements were resolved by consensus.
Data Extraction and Quality Assessment
The final articles included were assessed independently
by two reviewers (P.Z. and J.W.). Data retrieved from the
reports included author, publication year, patient source,
histology, disease stage, test method, cutoff value, VEGF
positive, and survival data (Table 1). If data from any of the
above categories were not reported in the primary study,
items were treated as “not applicable.” We did not contact the
author of the primary study to request the information.
To assess trial methodology, publications were read
independently by two investigators (PZ and XQL) and given
a quality score according to Steele’s method,9 which designed
the methodological scale of biologic prognostic factors for
lung cancer on behalf of European Lung Cancer Working
Party. The overall score evaluated several dimensions of the
methodology, grouped into four main categories: scientific
design; description of the methods used to identify abnormal
VEGF expression; how well the results could be generalized;
and the analysis of the study data. A maximum of 10 points
could be given for each category; hence, the overall maxi-
mum score was 40 points. When an item was not applicable
in a study, the theoretically attributable points were not taken
into account. Final scores were expressed as percentages
ranging from 0 to 100%, with higher values indicating better
methodology.
Statistical Methods
The correlation between two continuous variables was
measured by the Spearman rank correlation coefficient. Non-
parametric tests were used to compare the distribution of
quality scores according to the value of a discrete variable.
For the quantitative aggregation of the survival results,
hazard ratios (HR) and their 95% confidence intervals (CIs)
were combined to give the effective value. When these
statistical variables were not given explicitly in an article,
they were calculated from available numerical data using
methods reported by Parmar et al.10
Heterogeneity of the individual HRs was calculated
with 2 tests according to Peto’s method.11 Meanwhile, het-
erogeneity test with I2 statistic and Q statistic was performed.
All the studies included were categorized by histology, dis-
ease stage, patient race, VEGF isoform, and laboratory tech-
niques used. Individual meta-analysis was conducted in each
subgroup. If HRs were found to have fine homogeneity, a
fixed effect model was used for secondary analysis; if not, a
random-effect model was used. In this meta-analysis, DerSi-
monian-Laird random effects analysis12 was used to estimate
the effect of VEGF overexpression on survival. By conven-
tion, an observed HR1 implies worse survival for the group
with VEGF overexpression. The impact of VEGF on survival
was considered to be statistically significant if the 95% CI did
not overlap with 1. Horizontal lines represent 95% CIs. Each
box represents the HR point estimate, and its area is propor-
tional to the weight of the study. The diamond (and broken
line) represents the overall summary estimate, with CI rep-
resented by its width. The unbroken vertical line is set at the
null value (HR  1.0).
Evidence of publication bias was sought using the
methods of Egger et al.13 and Begg et al.14 Moreover, con-
tour-enhanced funnel plot15 was performed to aid in inter-
preting the funnel plot. If studies appear to be missing in
areas of low statistical significance, then it is possible that the
asymmetry is due to publication bias. If studies seem to be
missing in areas of high statistical significance, then publica-
tion bias is a less likely cause of the funnel asymmetry.
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TABLE 1. Main Characteristics and Results of the Eligible Studies
First Author Year
Patients
Source Histology Stage
No. of
Pts Method Cutoff Positive (%)
HR
Estimation HR (95% CI)
Kadota16 2008 Japan NSCLC I–III 147 IHC 30% VEGF:45%
VEGFC:44%;
HR 2.00 (1.14–3.52)
1.80 (1.02–3.16)
Ohta17 2007 Japan NSCLC I 122 IHC VEGFA/C:
50%/10%
NA HR 1.50 (1.05–2.11)
1.34 (0.58–3.10)
Donnem18 2007 Norway NSCLC I–III 335 IHC CS VEGF:43%
VEGFC:31%
VEGFD:68%
Surv.curves 1.53 (1.23–1.83)
1.20 (0.80–1.60)
Maekawa19 2007 Japan AC I–III 55 RT-PCR VEGFC/R3
93.75/156.2
NA HR 2.30 (0.53–10.04)
0.49 (0.37–2.79)
Takenaka20 2007 Japan NSCLC I–IV 79 RT-PCR NA VEGF 47% Surv.curves 0.94 (0.46–2.52)
Yilmaz21 2007 Turkey NSCLC I–III 50 IHC 50% VEGF 26% HR 4.65 (1.54–14.7)
Yoo22 2007 Korea NSCLC I–III 219 IHC 5% VEGF 92% HR 1.06 (0.37–3.10)
Seto23 2006 Japan NSCLC I 60 IHC 10% VEGF 30% Surv.curves 2.00 (0.77–3.23)
Enatsu24 2006 Japan AC I–III 78 IHC 10% VEGF:68%
VEGFC 42%
HR 0.35 (0.09–1.33)
0.47 (0.141.57)
Huang25 2005 Japan NSCLC I–III 173 IHC 30% VEGF:53%
VEGFC:42%
Surv.curves 1.83 (1.32–2.54)
Kim26 2005 USA NSCLC I–II 74 IHC CS VEGF 72% HR 3.20 (0.84–5.70)
Yuan 200527 2005 Taiwan NSCLC I–IV 60 RT-PCR 8.75 VEGF 50% Surv.curves 1.42 (1.08–1.78)
Nishi 200528 2005 Japan AC I–III 100 IHC NA VEGF 22% Surv.curves 1.54 (1.28–1.80)
Tomita 200529 2005 Japan NSCLC PN2–III 60 IHC 20% VEGF 58% HR 0.95 (0.73–2.48)
Kojima30 2005 Japan NSCLC I–III 129 IHC CS VEGF:45.7%
VEGFC:43%
VEGFR3:57%
HR 2.01 (0.94–4.29)
1.65 (0.76–3.57)
2.01 (0.94–4.29)
Shimanuki31 2005 Japan NSCLC I–IIIA 62 ELISA 326 VEGF 50% Surv.curves 1.37 (0.76–1.93)
Iwasaki32 2004 Japan NSCLC I–III 71 ELISA 180 VEGF 39% HR 2.06 (1.02–4.78)
Mineo33 2004 Italy NSCLC Ib-IIa 51 IHC 25% VEGF 82% HR 3.62 (1.05–14.6)
Ogawa34 2004 Japan NSCLC I–IIIa 206 IHC NA VEGFC 61% HR 1.72 (1.09–2.73)
Saad35 2004 USA NSCLC I 50 IHC 20% VEGF 66% Surv.curves 1.64 (1.49–1.79)
Tanaka36 2004 Japan NSCLC I 162 IHC CS VEGF 38.9% HR 1.64 (0.82–3.31)
Talbot37 2004 USA SCC NA 34 PCR NA VEGF:NA Surv.curves 2.05 (1.34–2.86)
Arinaga38 2003 Japan NSCLC I–III 180 IHC VEGFC/R3:
30%/NA
VEGFC:76.1%
VEGFR3:22%
HR 1.37 (0.97–1.89)
Liang39 2003 China NSCLC I–IV 55 IHC 30% NA Surv.curves 1.26 (1.08–1.44)
Brattstrom 200240 2002 Sweden NSCLC I–IV 58 ELISA 500 VEGF:21% Surv.curves 1.62 (0.740–4.26)
Inoshima41 2002 Japan NSCLC I–IV 132 IHC CS VEGF 49% HR 2.33 (1.26–4.26)
Minami42 2002 Japan AC I 42 IHC 30% VEGF 70% HR 0.83 (0.39–1.27)
Tanaka43 2002 Japan NSCLC I–III 236 IHC CS VEGF 34% HR 1.38 (0.79–2.42)
Shou Y44 2001 Japan NSCLC I–III 111 IHC NA VEGF 65% Surv.curves 2.40 (0.84–3.47)
Masuya45 2001 Japan NSCLC I–III 181 RT-PCR 1% VEGF 25% HR 1.77 (1.08–2.90)
Niklinska46 2001 Poland NSCLC I–III 89 IHC 70% VEGF 20% HR 2.56 (1.01–6.49)
Liao47 2001 China NSCLC I–III 127 IHC 25% VEGF 41% HR 1.18 (0.69–2.01)
Koukourakis48 2000 Greece NSCLC I–II 93 IHC 50% VEGF 47% HR 1.16 (0.65–2.07)
O’Byrne49 2000 UK NSCLC I–III 183 IHC 70% VEGF 47 HR 1.56 (1.05–2.32)
Ohta50 2000 Japan NSCLC I 122 IHC VEGFA/C:
50%/10%
VEGFA:80%
VEGFC:45%
HR 2.60 (1.40–4.90)
1.34 (0.583.10)
Sheng51 2000 Japan NSCLC I–IV 98 IHC 5% VEGF 51% HR 3.36 (1.44–7.87)
Konishi52 2000 Japan NSCLC I–III 181 IHC CS VEGF 25% HR 1.77 (1.08–2.91)
Yano53 2000 Japan NSCLC I–IV 108 IHC 25% VEGF 45% HR 0.49 (0.34–2.58)
Fontanini54 1999 Italy NSCLC I–III 42 RT-PCR NA VEGF 79% HR 4.55 (1.27–16.30)
Shibusa55 1998 Japan AC I 44 IHC NA VEGF 61% Surv.curves 6.37 (0.92–11.50)
Oshika56 1998 Japan NSCLC NA 84 RT-PCR/IHC NA VEGF 90/40% HR 3.95 (1.29–12.12)
Imoto57 1998 Japan NSCLC I–III 91 IHC ELISA HIC:5%
ELISA:525
IHC: VEGF 53% HR 2.59 (1.37–4.88)
(Continued)
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Intercept significance was determined by the t test suggested
by Egger (p  0.05 was considered representative of statis-
tically significant publication bias). All calculations were
performed using STATA version 9.0 (Stata Corporation,
College Station, TX).
RESULTS
Study Selection and Characteristics
Three hundred and six potentially relevant citations
were reviewed, and 51 studies met the criteria set forth in the
search strategy and study selection section (Figure 1). Fifty-
one studies16–66 published between 1997 and 2008 were
eligible for this systematic review with meta-analysis. All
reported the prognostic value of VEGF status for survival in
patients with lung cancer. The total number of patients
included was 5386, ranging from 34 to 335 patients per
study (median, 91). Two publications67,68 were excluded as
they were redundant with other included studies. The
major characteristics of the 51 eligible publications are
reported in Table 1.
These publications followed several different patient
cohorts. Forty-six studies dealt with all types of NSCLC,
whereas five dealt with SCLC. The NSCLC studies consid-
ered either all lung cancer subtypes (n  46), adenocarcino-
mas (n 5), or squamous cell carcinomas (n 2). Forty-five
studies had information for stages I–III, seven for stage I disease,
and only one for all stages I–IV. In all patients with NSCLC,
surgery was performed as the foremost treatment measure.
Thirty-five studies used IHC to evaluate VEGF expres-
sion in NSCLC, six studies used RT-PCR to assess VEGF
mRNA overexpression in NSCLC, and four studies used ELISA
to determine VEGF expression. VEGFC and VEGFR3/flt-1
were detected in eight and four studies, respectively.
Among the 44 studies evaluating VEGF expression in
NSCLC, 30 studies (3458 patients: 71.2%) were performed in
Asian populations, and the remaining 14 studies (1368 pa-
tients: 28.8%) followed European or American patients.
Twenty-eight of the 51 studies identified VEGF overexpres-
sion as an indicator of poor prognosis, and the other 23
studies showed no statistically significant impact of VEGF
overexpression on survival. The proportion of patients exhib-
iting VEGF overexpression in individual studies ranged from
22 to 81% by IHC, from 15 to 79% by RT-PCR, and from 31
to 53% by ELISA.
Quality Assessment
Overall, the global quality score of the included studies
ranged from 42.5 to 65.0% with a mean of 52.5% (Table 2).
Concerning the global score, there was no statistically signif-
icant difference between the 32 positive and the 19 negative
trials (mean of 53.8% versus 50.3%, p  0.624).
There was no statistical difference in global score between
studies that assessed VEGF status with IHC (n  39) or with
molecular biology (RT-PCR or ELISA) (n 12), with scores of
45.5% and 47.3%, respectively (p 0.896). However, there was
a significant difference for the description of the laboratory
methodology, with molecular biology better described than IHC
(5.2 of 10 compared with 4.6 of 10, p  0.025).
Meta-Analysis
The results of the meta-analysis are reported in Table 3
and in Figure 2. Overall, the combined HR for all 44 eligible
FIGURE 1. The flow diagram of search strategy.
TABLE 1. Continued
First Author Year
Patients
Source Histology Stage
No. of
Pts Method Cutoff Positive (%)
HR
Estimation HR (95% CI)
Giatromanolaki58 1998 Greece NSCLC I–III 114 IHC NA VEGF 68% HR 1.32 (0.73–2.39)
Takanami59 1997 Japan AC I–IV 118 IHC NA VEGF:58%; flt:55% HR 1.56 (0.93–2.61)
Volm60 1997 Germany SCC I–IIIa 109 IHC CS VEGF:59%; flt-1:68% Surv.curves 1.35 (0.82–2.24)
Fontanini61 1997 Italy NSCLC I–III 104 IHC 40% VEGF 44% HR 3.95 (1.86–8.41)
Hasegawa62 2005 Japan SCLC I–IV 45 ELISA 500 VEGF 31% HR 3.29 (1.34–8.09)
Dowell63 2004 USA SCLC I–IV 54 IHC NA VEGF 81% Surv.curves 0.87 (0.43–1.32)
Fontanini64 2002 Italy SCLC I–III 53 IHC 50% VEGF 42% HR 2.51 (1.17–5.38)
Lucchi65 2002 Italy SCLC I–III 87 IHC 50% VEGF 56% Surv.curves 1.63 (1.31–1.95)
Salven66 1998 Finland SCLC I–IV 68 ELISA 527 NA HR 1.50 (1.00–2.30)
VEGF, vascular endothelial growth factor; IHC, immunohistochemistry; ELISA, enzyme linked immunosorbent assay; RT-PCR, reverse transcription-polymerase chain reaction;
AC, adenocarcinoma; SCC, squamous cell carcinoma; NS, not significant; NA, not applicable; LD, limited disease; ED, extensive disease; HR, hazard ratio; CS, complex score
combining intensity and percentage.
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studies evaluated VEGF expression in NSCLC was 1.47
(95% CI: 1.38–1.54), indicating that VEGF overexpression
was an indicator of poor prognosis for NSCLC patients.
However, highly significant heterogeneity was detected
among these studies (Q  64.4, I2 33.3%, p  0.019).
When grouped according to the geographic settings of indi-
vidual studies, the combined HRs of Asian studies and
non-Asian studies were 1.35 (95% CI: 1.24–1.46) and 1.61
(95% CI: 1.49–1.73), respectively (Figure. 2A). When
grouped according to the method of VEGF detection used,
the combined HR was 1.46 (1.38–1.55) for IHC and 1.52
(1.23–1.81) for RT-PCR, again suggesting that VEGF over-
expression is associated with low survival rates.
The data extracted were adequate to aggregate the
studies of stage I NSCLC, adenocarcinoma, and SCLC for
subgroup analyses. We found one significant correlation,
between VEGF expression and stage I NSCLC. When we
aggregated seven studies that reported results for stage I
NSCLC, the combined HR was statistically significant: HR
1.57 (95% CI: 1.43–1.70, Q 16.7, I2 64.2%, p 0.01 for
heterogeneity) (Figure 2D). We also observed a statistically
significant effect of VEGF expression on survival in patients
with adenocarcinoma with an HR of 1.27 (95% CI: 1.06–
1.47, Q  20.5, I2  80.5%, p  0.00 for heterogeneity)
(Figure 2B) and in patients with SCLC with an HR of 1.41
(95% CI: 1.17–1.65, Q  9.8, I2  59.1%, p  0.04 for
heterogeneity) (Figure 2C). There were not adequate data to
aggregate studies of stage II or III NSCLC.
However, no statistically significant effect on survival
was observed for VEGF subtype. When we limited the
analysis to the eight studies that investigated VEGFC expression
in patients with NSCLC, the combined HR was 1.22 (95% CI:
0.96–1.47, Q  6.36, I2  0, p  0.499 for heterogeneity)
(Figure 2E). When the four studies investigating VEGFR3/flt-1
expression in patients with NSCLC were analyzed, the com-
bined HR was 1.58 (95% CI: 0.96–2.20, Q  5.2, I2  42.6%,
p  0.156 for heterogeneity) (Figure 2F).
Publication Bias
Begg’s funnel plot and Egger’s test were performed to
assess the publication bias in the literature. All 44 eligible
studies investigating patients with NSCLC yielded a Begg’s
test score of p  0.058 and an Egger’s test score of p 
0.096, meanwhile according to the contour-enhanced funnel
plot of 44 studies (Figure 3), the absence of publication bias
was found in all 44 studies. Similar results were found for the
five SCLC studies (p  0.462 and 0.781); 5 studies of
patients with adenocarcinoma (p  0.462 and 0.737); 7
studies including patients with stage I NSCLC (p  0.23 and
0.659); 8 studies investigating EVGFC expression in patients
with NSCLC (p  1.00 and 0.99) (data not shown); and 4
studies investigating VEGFR3/flt-1 expression in patients
TABLE 2. Results of the Methodological Assessment by the European Lung Cancer Working Party Score
Studies n Global Score % Designa Laboratory Methodologya Generalizabilitya Results Analysisa
All studies 51 52.5 5.1 5.1 5.5 5.3
Negative 19 50.3 4.7 5.1 5.1 5.2
Positive 32 53.8 5.3 5.1 5.2 5.3
p 0.621 0.326 0.916 0.43 0.962
IHC 39 45.5 3.9 4.6 4.7 4.9
MB 12 47.3 3.9 5.2 4.7 5.2
p 0.896 0.896 0.025 0.303 0.305
Score distributions are summarized by the median values; Negative, no significant prognostic factor for survival; poor, as significant positive prognostic factor for survival; IHC,
immunohistochemistry; MB, molecular biology (reverse transcription-polymerase chain reaction and enzyme linked immunosorbent assay).
aScore out of 10.
TABLE 3. Meta-Analysis: HR Value in Lung Cancer Subgroups According to Histology, Stage,
Subtype of VEGF, and Methods Detected VEGF
Nb Patients Random Effects HR (95% CI) Heterogeneity Test (Q, I2, P)
VEGF in NSCLC 44 4826 1.46 (1.38–1.54) 64.4, 33.3%, 0.019
Asian 30 3458 1.35 (1.24–1.46) 44.6, 35.0%, 0.032
Non-Asian 14 1368 1.61 (1.49–1.73) 10.1, 0%, 0.687
VEGF in NSCLC by IHC 35 4173 1.46 (1.38–1.55) 58.8, 42.2%, 0.005
VEGF in NSCLC by RT-PCR 6 480 1.52 (1.23–1.81) 5.1, 1.7%, 0.405
VEGF in SCLC 5 307 1.41 (1.17–1.65) 9.79, 59.1%, 0.044
VEGF in Adenocarcinoma 5 380 1.27 (1.06–1.47) 20.5, 80.5%, 0.000
VEGF in stage I NSCLC 7 602 1.57 (1.43–1.70) 16.7, 64.2%, 0.010
VEGFC in NSCLC 8 1252 1.22 (0.96–1.47) 6.36, 0%, 0.499
VEGFR3/flt-1 in NSCLC 4 411 1.58 (0.96–2.20) 5.22, 42.6%, 0.156
Nb, number of studies; VEGFC, vascular endothelial growth factor C; flt-1, fetal liver kinase 1; VEGFR3, vascular endothelial growth
factor receptor 3; RT-PCR, reverse transcription-polymerase chain reaction; IHC, immunohistochemistry; HR, hazard ratio; CI, confidence
interval; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer.
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with NSCLC (p  0.308 and 0.157). These results suggest
that there is no publication bias at work.
DISCUSSION
Since the publication of Folkman’s innovative tumor
angiogenesis hypothesis in 1971,69 there has been great in-
terest in understanding the role of VEGF in this process.
Reports of the prognostic value of VEGF expression in
NSCLC patients date back to the 1990s. However, the first
VEGF-targeting drug (bevacizumab) developed as an inhib-
itor of angiogenesis was not approved by the US Food and
Drug Administration until 2004.70 A true understanding of
the mechanism of action of anti-VEGF therapies requires
more accurate evaluation of the impact of VEGF expression
on patient survival.
In this systematic review with meta-analysis, we have
combined 51 published studies including 5386 patients with
lung cancer to yield summary statistics that indicate that
VEGF overexpression has a significant correlation with poor
survival in patients with NSCLC and SCLC. This correlation
was observed in both Asian and non-Asian study populations.
When analysis was restricted to stage I NSCLC, we found
that the combined HR (1.57) was larger than the combined
HR for all 44 eligible studies of stages I–III NSCLC (1.46),
FIGURE 2. Meta-analysis (Forest plot) of the 44 evaluable studies assessing vascular endothelial growth factor (VEGF) in non-
small cell lung cancer (NSCLC) (A); the five evaluable studies assessing VEGF in adenocarcinoma (B); the five evaluable studies
assessing VEGF in small cell lung cancer (SCLC) (C); the seven evaluable studies assessing VEGF in stage I NSCLC (D); the
eight evaluable studies assessing VEGFC in NSCLC (E); the four evaluable studies assessing vascular endothelial growth factor
receptor 3/Flt-1 in NSCLC (F).
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suggesting that VEGF expression could be an important
prognostic factor for early-stage NSCLC. When we limited
our analysis to adenocarcinoma, we found a worse prognostic
significance of VEGF. Data were not sufficient to determine
the prognostic value of VEGF expression in squamous cell
carcinoma. The method used to detect VEGF did not have an
impact on significance; results were similar for studies that
used IHC or RT-PCR.
Subgroup analyses revealed that neither VEGFC over-
expression nor VEGFR3/flt-1 had a significant impact on
survival of NSCLC patients. VEGFC was a specific inducer
of mediated lymphangiogenesis.71 VEGFC expression levels
are increased in many malignant tissues, including lung
cancers. However, the value of VEGFC expression as a
prognostic tool for NSCLC has been controversial. Unfortu-
nately, our meta-analysis further supports the hypothesis that
VEGFC overexpression is not associated with survival in
NSCLC patients.
The present systematic review with meta-analysis sug-
gests that VEGF overexpression is an indicator of poor
prognosis for patients with SCLC. Thus, inhibiting VEGF-
mediated angiogenesis might be an effective treatment for
SCLC, in combination with chemotherapy. Recently, several
phase 2 trials72,73 have shown some clinical benefits for the
VEGF-targeting monoclonal antibody bevacizumab in pa-
tients with untreated extensive disease-SCLC. Meanwhile,
phase 3 trials of bevacizumab as a first-line therapy in
patients with extensive disease-SCLC are planned for the
near future.74
Recently, several systematic reviews9,75–82 with meta-
analyses on other biologic prognostic factors for NSCLC had
been reported. P53, microvessel density, HER-2, Ki-67, and
RAS might be poor prognostic factors for survival in
NSCLC, however, Bcl-2 might be better prognostic factor for
survival in NSCLC. The prognostic significance of EGFR
and Survivin had been under controversy. Moreover, several
studies83–85 had reported that the expression of VEGF, Gult-1
(glucose transporter 1), and microvessel density were all
significantly correlated with 18F-FDG (2–18F-fluoro-2-de-
oxy-D-glucose) uptake of positron emission tomography-
computed tomography, these three biomarkers showed a
positive correlation with the 18F-FDG uptake.
Our data were consistent with the results of a previous
meta-analysis86 published in French that showed an associa-
tion between VEGF overexpression and poor survival of
patients with NSCLC. This analysis included only 15 studies,
FIGURE 2. Continued.
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and the data were insufficient to determine the prognostic
value of VEGF in SCLC. In addition, that meta-analysis did
not determine the combined HR for subgroups divided ac-
cording to histology, disease stage, and subtype of VEGF or
method of VEGF detection. We have improved upon that
previous meta-analysis by including more recent related stud-
ies and by generally using a more comprehensive search
strategy. Screening, study selection, and quality assessment
were performed independently and reproducibly by two re-
viewers. We also explored heterogeneity and potential pub-
lication bias in accordance with published guidelines.
This systematic review with meta-analysis was compli-
cated by heterogeneity issues. We found highly significant
heterogeneity among 44 studies of NSCLC and five studies of
SCLC. When the analysis was limited to 14 non-Asian
studies of NSCLC and 8 studies of VEGFC expression in
NSCLC, heterogeneity was not detected, but heterogeneity
was detected when analyses were limited to the five studies
including only adenocarcinomas or seven studies including
only stage I NSCLC. Therefore, histologic type and disease
stage were not a major source of heterogeneity. The hetero-
geneity in this study could be explained by the patient type or
by differences in the method used to detect VEGF status.
Thirty-five of the studies included in our analysis used IHC to
detect VEGF, four used ELISA, and six used RT-PCR. When
analyzed separately, heterogeneity was still found in the 35
studies that used IHC; however, no heterogeneity was found
among the six studies that used RT-PCR.
Diversity within the techniques used to identify alter-
ation of the VEGF status is another potential source of bias.
The technique used for IHC varies considerably among the 35
studies in our analysis. The primary antibodies used were not
identical, and many different cutoffs for VEGF positive
tissues (10–50%, different scores) were used. To exclude
technique bias, subgroup analyses were performed for the
most frequently used methods: IHC, ELISA, and RT-PCR.
The results were consistent within all methods, with poorer
survival in cases where VEGF was overexpressed, suggesting
that the techniques are unlikely to be a source of bias.
However, it is still important to use well defined, standardized
methods to reproducibly evaluate biologic markers.
Another potential source of bias is related to the method
of HR and 95% CI extrapolation. If these statistics were not
reported by the authors, we calculated them from the data
available in the article. If this was not possible, we extrapo-
lated them from the survival curves, necessarily making
assumptions about the censoring process. Data for multivar-
iate survival analysis reported in the article were included in
the present systematic review with meta-analysis; if these
data were not available, data calculated from survival curves
by univariate analysis were included. These results should be
confirmed by an adequately designed prospective study. Fur-
thermore, the exact value of VEGF overexpression status
needs to be determined by appropriate multivariate analysis.
Unfortunately, few prospectively designed prognostic studies
concerning biomarkers have been reported; thus, our collec-
tion of many retrospective studies revealed more significance.
Additional biases could be introduced by the method-
ology used to perform our systematic review with meta-
analysis. We performed a methodological assessment of the
studies to avoid selection biases where possible. The absence
of a detectable difference in quality score between significant
and nonsignificant studies, and between evaluable and non-
evaluable studies, encouraged us to perform a meta-analysis
of the results from the individual trials.
Publication bias87 is a major concern for all forms of
meta-analysis; positive results tend to be accepted by jour-
nals, while negative results are often rejected or not even
submitted. The present analysis does not support publication
bias; the obtained summary statistics likely approximate the
actual average. However, it should be noted that our meta-
analysis could not completely exclude biases. For example,
the study was restricted to articles published in English and
Chinese, which probably introduced bias.
In conclusion, VEGF overexpression was associated
with a poor prognosis in patients with lung cancer in the
present systematic review with meta-analysis. Interestingly,
our meta-analysis suggests that VEGF has a detrimental
effect on survival in stage I NSCLC. Use of VEGF as a
prognostic tool at the earliest stage of NSCLC could be of
clinical interest to allow the selection of patients eligible for
induction or adjuvant chemotherapy. However, VEGFC and
VEGFR3/flt-1 overexpression seems to have no significant
impact on survival of NSCLC patients, as determined in our
meta-analysis. These results should be confirmed by an ade-
quately designed prospective study.
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